COLLCOLLHealthcare · Drug Manufacturers - Specialty & Generic

COLL Stock Forecast: Collegium Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$26
+1.49% on the day

The 8 Wall Street analysts covering Collegium Pharmaceutical, Inc. hold a median 12-month price target of $45 — +71.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 17 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$794.0M
Ticker Nerd rank
72/ 100
Median analyst target
$45
Analysts covering
8
Revenue$199.9M+6.3% y/y
Operating income$3.7M
Net income−$15.1M
Free cash flow$70.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.5%
1M
+11.8%
YTD
−44.0%
1Y
−42.8%
From 52W high
−48.0%
From 52W low
+20.4%
$22
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COLL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Collegium Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
72/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
92
Volatility
84
Accruals
66
Growth
47
Revisions
46
Size
46
Issuance
45
Momentum
36

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (36): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

COLL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COLL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26COLLHigh $60Median $45Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $28Median $45High $60

The green dot is the last close — the median target sits +71.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
16 Nov 2026BarclaysMaintainsOverweight$48 → $41
6 Nov 2026Piper SandlerMaintainsNeutral$43 → $28
5 Nov 2026NeedhamMaintainsBuy$46 → $44
23 Sept 2026OppenheimerInitiatesOutperform—
23 Sept 2026OppenheimerInitiatesOutperform$50
9 Sept 2026Leerink PartnersInitiatesOutperform$45
9 Sept 2026Leerink PartnersInitiatesOutperform—
9 Sept 2026Truist SecuritiesMaintainsBuy$58 → $49
9 Sept 2026Truist SecuritiesMaintainsBuy—
19 Aug 2026BarclaysMaintainsOverweight—
19 Aug 2026BarclaysMaintainsOverweight$56 → $48
7 Aug 2026Piper SandlerReiteratesNeutral—
7 Aug 2026Piper SandlerReiteratesNeutral$45 → $43
6 Aug 2026NeedhamMaintainsBuy—
6 Aug 2026NeedhamMaintainsBuy$56 → $46
20 Mar 2026HC Wainwright & Co.ReiteratesBuy$60
20 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026NeedhamReiteratesBuy$54 → $56
19 Mar 2026NeedhamReiteratesBuy—
26 Feb 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

COLL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

COLL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Collegium Pharmaceutical, Inc. returned −42.8% against +12.2% for the S&P 500, dividends included.

COLL vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26COLLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COLL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−0.9%
Analysts raising
3
Analysts cutting
4
Fundamentals

Collegium Pharmaceutical, Inc. (COLL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.4×

Cheaper than 32% of US stocks

Price / sales
1.0×

Cheaper than 68% of US stocks

Price / book
2.7×

Cheaper than 33% of US stocks

EV / EBITDA
4.4×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
3.3%

Higher than 36% of US stocks

Earnings growth (YoY)
−30.9%

Higher than 16% of US stocks

Gross margin
55.2%

Higher than 68% of US stocks

Operating margin
22.9%

Higher than 84% of US stocks

Net margin
4.7%

Higher than 58% of US stocks

Returns & dividend
Return on equity
13.4%

Higher than 71% of US stocks

Return on assets
6.3%

Higher than 82% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Collegium Pharmaceutical, Inc. (COLL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Collegium Pharmaceutical, Inc. has a market value of $794.0M and an enterprise value of $1.9B.

  • Revenue in the twelve months to 30 June 2026: $808.2M. The latest quarter grew 3.3% year on year.

  • Net income over the same four quarters: $47.9M, a 5.9% net margin.

  • Diluted earnings per share, trailing twelve months: $1.24.

  • Free cash flow in the twelve months to 30 June 2026: $328.3M.

  • Shares outstanding: 32.5M.

  • Trailing P/E: 23.4×; forward P/E: 3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Collegium Pharmaceutical, Inc. employs 357 people — $2.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

COLL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
COLLCollegium Pharmaceutical, Inc.$794.0M72
IRWDIronwood Pharmaceuticals, Inc.$794.1M100
HROWHarrow, Inc.$1.1B42
AMPHAmphastar Pharmaceuticals, Inc.$1.3B94
TKNOAlpha Teknova, Inc.$472.0M93
AQSTAquestive Therapeutics, Inc.$464.4M67
PAHCPhibro Animal Health Corp.$1.4B92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Collegium Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COLL news & analysis

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Zacks Investment Research · 17 Nov 2026neutral

Zacks Investment Research describes its stock-picking approach as focused on earnings estimates and estimate revisions, while also tracking value, growth, and momentum trends. The headline asks whether Collegium Pharmaceutical is a great value stock but the excerpt gives no company-specific conclusion.

Why it matters — COLL watchers may note the article frames the question around value alongside Zacks’ broader emphasis on earnings estimates and market trends.

Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade

Zacks Investment Research · 10 Nov 2026positive

Zacks reports that analysts’ average price target for Collegium Pharmaceutical implies 81.6% upside, while noting this metric has not been reasonably effective. It also says strong agreement among analysts in raising earnings estimates indicates potential upside.

Why it matters — COLL watchers may note the analyst estimate revisions alongside the caveat about the limited effectiveness of price targets.

Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript

Seeking Alpha · 8 Nov 2026neutral

Collegium Pharmaceutical held its Q3 2026 earnings call on November 5, 2026. The excerpt lists company representatives and participating analysts but provides no discussion of results or outlook.

Why it matters — The call is a company update for COLL watchers, though this excerpt contains no financial or operating details to assess.

Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates

Zacks Investment Research · 5 Nov 2026positive

Collegium Pharmaceutical reported Q3 earnings of $1.96 per share, above the Zacks Consensus Estimate of $1.77. Earnings were $2.25 per share a year earlier.

Why it matters — The report gives COLL watchers an update on quarterly earnings relative to the consensus estimate and the year-ago period.

Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics

Zacks Investment Research · 5 Nov 2026neutral

Zacks Investment Research notes that Collegium Pharmaceutical’s Q3 headline results for the quarter ended September 2026 can be assessed against Wall Street estimates and year-ago actuals. The excerpt does not provide the results or comparisons.

Why it matters — These comparisons can help COLL watchers evaluate quarterly performance, but the excerpt gives no figures or direction of results.

FAQ

Frequently asked questions about COLL stock

What is the COLL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Collegium Pharmaceutical, Inc. have a median 12-month price target of $45, with estimates ranging from $28 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COLL stock a buy right now?

Of the 8 analysts covering Collegium Pharmaceutical, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Collegium Pharmaceutical, Inc. 72 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COLL?

As at 17 Nov 2026, Collegium Pharmaceutical, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will COLL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +71.6% from the last close, and Ticker Nerd's factor model ranks Collegium Pharmaceutical, Inc. 72 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COLL stock forecast for 2030?

No analyst covering Collegium Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $60 over the next 12 months.

How has COLL stock performed over the past year?

Collegium Pharmaceutical, Inc. returned -42.8% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Collegium Pharmaceutical, Inc. do?

Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD).

What is the latest news on COLL?

The most recent item we track (Zacks Investment Research, 17 Nov 2026): "Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?". Zacks Investment Research describes its stock-picking approach as focused on earnings estimates and estimate revisions, while also tracking value, growth, and momentum trends. The headline asks whether Collegium Pharmaceutical is a great value stock but the excerpt gives no company-specific conclusion.

Company

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD). Its current portfolio includes branded prescription products such as Xtampza ER, Belbuca, the Nucynta franchise, Jornay PM, and Symproic, serving patients with complex and chronic medical conditions. The company emphasizes differentiated drug-delivery technology and responsible pain-management therapies, with its business centered on the U.S. market. Collegium Pharmaceutical, Inc. also supports its products through commercial operations, market access, and patient support activities, making it a notable participant in branded specialty pharmaceuticals.

CEO Mr. Vikram Karnani · 357 employees · United States · https://www.collegiumpharma.com